An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer.
Pugh, Trevor J TJ; Bell, Jonathan L JL; Bruce, Jeff P JP; Doherty, Gary J GJ; Galvin, Matthew M; Green, Michelle F MF; Hunter-Zinck, Haley H; Kumari, Priti P; Lenoue-Newton, Michele L ML; Li, Marilyn M MM; Lindsay, James J; Mazor, Tali T; Ovalle, Andrea A; Sammut, Stephen-John SJ; Schultz, Nikolaus N; Yu, Thomas V TV; Sweeney, Shawn M SM; Bernard, Brady B; ,
Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study.
Frontiers In Oncology
Shen, Fangfang F; Liang, Naixin N; Fan, Zaiwen Z; Zhao, Min M; Kang, Jing J; Wang, Xifang X; Hu, Qun Q; Mu, Yongping Y; Wang, Kai K; Yuan, Mingming M; Chen, Rongrong R; Guo, Wei W; Dong, Guilan G; Zhao, Jun J; Bai, Jun J
Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.
Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.
Frontiers In Oncology
Mahfoudhi, Emna E; Ricordel, Charles C; Lecuyer, Gwendoline G; Mouric, Cécile C; Lena, Hervé H; Pedeux, Rémy R
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy.
Cancers
Canale, Matteo M; Andrikou, Kalliopi K; Priano, Ilaria I; Cravero, Paola P; Pasini, Luigi L; Urbini, Milena M; Delmonte, Angelo A; Crinò, Lucio L; Bronte, Giuseppe G; Ulivi, Paola P
Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non-Small-Cell Lung Cancer and Other Cancer Types.
Jco Precision Oncology
Yin, Yan Y; Song, Lijie L; Shi, Dongsheng D; Liu, Bin B; Li, Xiangke X; Yang, Minjie M; Liu, Bihao B; Wang, Dejuan D; Qin, Jianwen J
Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review.
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Nature
Robichaux, Jacqulyne P JP; Le, Xiuning X; Vijayan, R S K RSK; Hicks, J Kevin JK; Heeke, Simon S; Elamin, Yasir Y YY; Lin, Heather Y HY; Udagawa, Hibiki H; Skoulidis, Ferdinandos F; Tran, Hai H; Varghese, Susan S; He, Junqin J; Zhang, Fahao F; Nilsson, Monique B MB; Hu, Lemei L; Poteete, Alissa A; Rinsurongkawong, Waree W; Zhang, Xiaoshan X; Ren, Chenghui C; Liu, Xiaoke X; Hong, Lingzhi L; Zhang, Jianjun J; Diao, Lixia L; Madison, Russell R; Schrock, Alexa B AB; Saam, Jennifer J; Raymond, Victoria V; Fang, Bingliang B; Wang, Jing J; Ha, Min Jin MJ; Cross, Jason B JB; Gray, Jhanelle E JE; Heymach, John V JV
Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC.
Targeted Oncology
Wei, Jiacong J; Meng, Pei P; Terpstra, Miente Martijn MM; van Rijk, Anke A; Tamminga, Menno M; Scherpen, Frank F; Ter Elst, Arja A; Alimohamed, Mohamed Z MZ; Johansson, Lennart F LF; Stigt, Jos J; Gijtenbeek, Rolof P G RPG; van Putten, John J; Hiltermann, T Jeroen N TJN; Groen, Harry J M HJM; Kok, Klaas K; van der Wekken, Anthonie J AJ; van den Berg, Anke A
Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments.